We’re happy to announce that TRACER will be attending the annual congress of the European Association of Nuclear Medicine (EANM). From Oct. 4 to 8, we will participate in one-on-one meetings under the Barcelona sun.
For you as a drug developer, this is a great chance to explore opportunities in clinical translation, fluorescent and nuclear imaging, and fast-track clinical trials. Fill out the contact form on this page to schedule your meeting with us.
We are excited to meet you!
Learn more about exploratory trials (Phase 0/Early Phase 1
We like to share the most important information on Phase 0 clinical trials. In our meeting we will elaborate on this, and there will be time to answer all of your questions.
- Approved method by FDA, EMA, and other ICH regions
- Higher chance of success in subsequent trials
- First patient in within 6 months
- On- /off-target data in approximately 12 months
- GLP material is sufficient
- Only limited toxicity studies needed
- Skip large animal studies, only a rodent study is mandatory
- Significantly lower investment in comparison to Phase I
Fill out the form on this page to schedule your meeting at the EANM congress, or send an e-mail to info@tracercro.com.